Ask AI
ProCE Banner Activity

CE / CME

H3 K27–Altered Diffuse Midline Glioma From Biopsy to Treatment: Neurosurgical Decisions in the Era of Molecularly Directed Therapy

Video

In this on-demand webinar on the neurosurgical management of H3 K27–altered diffuse midline glioma (DMG), expert faculty focus on the role of stereotactic biopsy, molecular diagnosis, and treatment planning. Topics include evaluating the risks and benefits of tissue acquisition based on tumor location and clinical presentation; optimizing biopsy techniques and tissue stewardship to support integrated molecular diagnosis; and interpreting H3 K27M immunohistochemistry, H3K27me3 assessment, sequencing, and cerebrospinal fluid tumor DNA testing. The slides also review clinical evidence supporting dordaviprone in progressive H3 K27–mutant DMG, the ongoing phase III ACTION trial, and investigational approaches including ONC206 and CAR T-cell therapies targeting GD2 and B7-H3. Additional considerations include managing neurologic deterioration and hydrocephalus, coordinating multidisciplinary care, and optimizing referral timing and procedural planning to preserve treatment and clinical trial opportunities.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: November 20, 2026

Expiration: May 19, 2027

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for neurosurgeons, pediatric neurosurgeons, neurosurgical oncologists, neurosurgical fellows, and residents who evaluate or manage patients with diffuse midline glioma. 

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, competence, and confidence in obtaining a precise molecular diagnosis of H3 K27-altered DMG, integrating neurosurgical decision-making with current systemic treatment, and coordinating timely referral for multidisciplinary care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine when stereotactic biopsy is likely to meaningfully alter diagnosis, treatment eligibility, or clinical trial access in patients with suspected DMG, considering tumor location, procedural risk, neurologic status, and alternatives to tissue acquisition

  • Apply neurosurgical tissue-acquisition and specimen-stewardship strategies that support integrated diagnosis through coordinated use of H3 K27M IHC, H3K27me3 assessment, sequencing, and broader molecular testing, while recognizing the adjunctive role and current limitations of CSF-tDNA

  • Evaluate current evidence for systemic therapy in progressive H3 K27M-mutant DMG, including dordaviprone efficacy, safety, regulatory status, evidence limitations, and ongoing Phase III evidence generation, distinguishing approved use in progressive disease following prior therapy from investigational post-radiotherapy use in newly diagnosed disease

  • Coordinate neurosurgical management across the DMG continuum, including hydrocephalus and neurologic deterioration, consideration of repeat tissue or CSF acquisition, and timely referral for systemic, cellular, and locoregional clinical trials

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Gerald A. Grant, MD, MBA: consultant/advisor/speaker: Aesculap; other financial or material support: Medtronic.

Sanghee Lim, MD, PhD, has no relevant financial relationship to disclose.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 20, 2026, through May 19, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content, drafting educational content, and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to ​1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.​

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. ​

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported credit. Visit CME cmepassport.org to create your account.